# neovascular FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/neovascular

> No upcoming FDA catalysts in neovascular; 4 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| August 2, 2022 | [Lucentis® (ranibizumab) FDA approval](https://sec-api.dev/pdufa/ranibizumab) | CHRS | neovascular | completed, approved | "CIMERLI (ranibizumab-eqrn), a Lucentis biosimilar, was approved by the FDA on August 2, 2022 for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization and we launched CIMERLI commercially in the United States on October 3, 2022." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1512762/000110465925111484/chrs-20251113xex99d1.htm)) |
| August 2, 2022 | [Biosimilar FDA approval](https://sec-api.dev/pdufa/biosimilar) | CHRS | neovascular | completed, approved | "CIMERLI (ranibizumab-eqrn), a Lucentis biosimilar, was approved by the FDA on August 2, 2022 for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization and we launched CIMERLI commercially in the United States on October 3, 2022." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1512762/000155837025003126/chrs-20241231x10k.htm)) |
| Jan 2024 | [Eylea® (eylea) topline data readout](https://sec-api.dev/pdufa/eylea) | ALVO | neovascular | completed, positive | "In January 2024 Alvotech announced positive top-line results from a confirmatory clinical study with AVT06 (AVT06-GL-C01) comparing the efficacy, safety, and immunogenicity of the proposed biosimilar to Eylea® in patients with neovascular (wet) AMD." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184325004011/exh_991.htm)) |
| Jan 2024 | [PAVBLU® (aflibercept) topline data readout](https://sec-api.dev/pdufa/aflibercept) | ALVO | neovascular | completed, positive | "In January 2024, Alvotech announced positive top-line results from a confirmatory clinical study comparing the efficacy, safety, and immunogenicity of AVT06 to Eylea® (aflibercept) in patients with neovascular (wet) AMD." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184325008028/exh_991.htm)) |

## Drugs

- [Lucentis® (ranibizumab)](https://sec-api.dev/pdufa/ranibizumab) (ABBV)
- [Biosimilar](https://sec-api.dev/pdufa/biosimilar) (ALVO)
- [Eylea® (eylea)](https://sec-api.dev/pdufa/eylea) (REGN)
- [PAVBLU® (aflibercept)](https://sec-api.dev/pdufa/aflibercept) (REGN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/neovascular.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "neovascular FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/neovascular

```bibtex
@misc{secapidev_indications_neovascular_20261116,
  title        = {neovascular FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/neovascular}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_neovascular_20261116","title":"neovascular FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/neovascular","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
